StreetInsider.com News Articles

Form 8-K HARROW, INC. For: Jun 03

Wed, 03 Jun 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26596609.html

Form 8-K HARROW, INC. For: Jun 03

Wed, 03 Jun 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260603/26596609.html

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair’s 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

Wed, 27 May 2026 07:00:00 -0400

The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management

Form 4 HARROW, INC. For: May 18 Filed by: Graves Adrienne L

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517091.html

Form 4 HARROW, INC. For: May 18 Filed by: Graves Adrienne L

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517091.html

Form 4 HARROW, INC. For: May 18 Filed by: SILVERNAIL LAUREN P

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517094.html

Form 4 HARROW, INC. For: May 18 Filed by: SILVERNAIL LAUREN P

Tue, 19 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260519/26517094.html

Form 4 HARROW, INC. For: May 15 Filed by: Shojaei Amir

Mon, 18 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260518/26514867.html

Form 4 HARROW, INC. For: May 15 Filed by: Shojaei Amir

Mon, 18 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260518/26514867.html

Form 4 HARROW, INC. For: May 14 Filed by: BOLL ANDREW R.

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499196.html

Form 4 HARROW, INC. For: May 14 Filed by: BOLL ANDREW R.

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499196.html

Form 4 HARROW, INC. For: May 14 Filed by: BAUM MARK L

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499213.html

Form 4 HARROW, INC. For: May 14 Filed by: BAUM MARK L

Fri, 15 May 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26499213.html

Harrow Health (HROW) PT Lowered to $60 at B.Riley

Thu, 14 May 2026 08:55:10 -0400

B.Riley analyst Mayank Mamtani lowered the price target on Harrow Health (NASDAQ: HROW) to $60.00 (from $65.00) while maintaining a Buy rating.

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

Wed, 13 May 2026 10:13:46 -0400

MONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (Nasdaq: HROW) (“HROW”) has violated the federal securities laws after the company advised that VEVYE revenue of $20.9 million during the first quarter of 2026 was below expectations due to an estimated $8 million gross-to-net reduction associated with new commercial coverage for VEVYE.